Skip to main content

Table 1 Characteristics of included studies for the meta-analyses

From: Prognostic value of circulating tumor cells detected with the CellSearch system in esophageal cancer patients: a systematic review and meta-analysis

Reference Year Country Patient Age (years) Tumor stage Sampling time Target antigen/gene Cutoff Positive End point Treatment regimens
number male/female n male/female
Konczalla L 11 2019 Germany 76 27/19 65(NR) I—IV Baseline CK, CD45 ≥1/7.5 ml 15 10/5 OS/RFS Surgery
Woestemeier A 12 2018 Germany 45 35/10 63.3 I—III Baseline EpCAM, CK (8, 18, 19), CD45 ≥1/7.5 ml 7 6/1 OS/RFS Surgery
Tanaka M 23 2015 Japan 38 30/8 63 (43–87) I—IV Baseline EpCAM, CK (8, 18, 19), CD45 ≥2/7.5 ml 19 14/5 OS Chemotherapy/Chemoradiotherapy
    38 30/8 63 (43–87) I—IV intra-therapy EpCAM, CK (8, 18, 19), CD45 ≥2/7.5 ml 15 NR OS  
Matsushita D 24 2015 Japan 90 78/12 65 (46–98) II—IV Baseline EpCAM, CD45 ≥1/7.5 ml 25 22/3 OS Chemotherapy/Chemoradiotherapy
    71 NR NR NR intra-therapy EpCAM, CD45 ≥1/7.5 ml 15 NR NR  
Reeh M 25 2015 Germany 100 77/23 66 (32–85) I—IV Baseline EpCAM, CK, CD45 ≥1/7.5 ml 18 13/5 OS/RFS Surgery
Sclafani F 26 2014 U.K. 18 16/2 61 (38–78) NR Baseline EpCAM, CK CD45 ≥2/7.5 ml 8 NR OS NR
Hiraiwa K 27 2008 Japan 38 NR NR NR Baseline EpCAM, CK CD45 ≥2/7.5 ml 5 NR OS Chemotherapy
  1. OS Overall survival, DSF Disease-free survival, NR Not reported